HIF1A and COVID-19: Preventing transactivation of HIF-1α by peptide inhibitors of HIF-1/CBP-p300 interaction (previously shown to suppress tumor growth) (Kung et al., 2001; Qin et al., 2021) or other compounds with similar effects (Freedman et al., 2002; Jayatunga et al., 2015), could be interesting to test in order to evaluate their possible benefit in the treatment of COVID-19.